Cairo, Egypt - 12^th May 2025 - Cairo hosted a high-profile regional medical forum on the latest treatments for blood cancers, with the participation of an elite group of professors and specialized doctors from the United States, the United Kingdom, France, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Egypt. The forum discussed the latest global advancements in the diagnosis and treatment of blood disorders and cancers, with a focus on innovative treatments that enhance recovery chances and improve patients' quality of life.

The event, organized by BeiGene—a global oncology company soon to be known as BeOne Medicines—aimed to advance access to the latest cancer treatments in Egypt. It featured a series of scientific sessions and workshops highlighting recent developments in cancer care, including immunotherapy, targeted therapies, and promising clinical trials in both hematology and oncology. Experts from Egypt and the other countries emphasized the importance of international cooperation to transfer expertise and localize medical technology.

"This event represents a pivotal opportunity to connect global expertise with local practice, ensuring that patients in the region have access to the latest advancements in cancer treatment. Collaboration among healthcare specialists is key to transforming the oncology treatment landscape." stated Prof. Dr. Mubarak Almansour, Section Head, Oncology Department, Princess Princess Noorah Oncology Center King Abdulaziz Medical City, Ministry of National Guard Health Affairs

“Innovative treatments are changing the way we approach cancer, and it is essential that these breakthroughs reach patients everywhere. By bringing together international and regional experts and collaborating with leading pharmaceutical companies, we can accelerate progress and improve outcomes for those affected by this disease." confirmed Prof. Dr. Mohamed Moussa, Head of bone marrow transplantation unit and Professor of internal medicine & hematology in Ain Shams University.

Last month, a strategic partnership was signed between EVA Pharma, one of the fastest-growing healthcare companies in the Middle East and Africa, and BeiGene.
Dr. Riad Armanious, CEO of EVA Group said “We are committed to provide advanced and affordable therapeutic solutions to all patients who need them. Our partnership with BeiGene affirms the confidence in our technical and human capabilities, and through it, we aim to save thousands of patients annually by bridging the treatment gap and providing innovative healthcare solutions.”

Dr. Mohammed Al Kapany, General Manager of BeiGene’s Middle East and Africa (MENA) region, added: "We are eager to expand access to innovative treatments for patients in the region. This partnership with EVA Pharma represents a significant step toward achieving this goal, as we combine BeiGene’s technology with EVA’s local expertise to serve patients."

About EVA Pharma 

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind

capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products. 

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. 

Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology, andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. 

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. 

For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn & Instagram   

 

 

 

About BeiGene 

BeiGene Ltd., which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn.

Issued by: 

EVA Pharma, El Sharekat St., El Opera-Abdeen – Cairo - Egypt 
 
BeiGene International GmbH- Dubai branch “soon to be named BeOne Medicines International- UAE branch, Dubai Science Park, Al Barsha - Al Barsha South - Dubai - United Arab Emirates”. 

Date of Preparation: 

9 May 2025 

* 

END 

 

For media inquiries contact - BeiGene:

Louise Carter 

Email: louise.carter@beigene.com 

 

For media inquiries contact – EVA Pharma:

Ahmed Ellewa 

Email: ahmed.ellewa@evapharma.com